An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Novo Nordisk’s Awiqli® On March 26, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes.
This new approval offers the only once‑weekly basal insulin option, recognizing the importance of personalized care and the need for treatments that fit different patient routines and preferences for adults living with type 2 diabetes “Awiqli® is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It’s helping to reframe what basal insulin care can look like,” said Anna Windle, PhD, Group Vice President, Clinical Development, Medical & Regulatory Affairs at Novo Nordisk Inc.
“Awiqli® may address challenges associated with the frequency of daily basal injections, by reducing them from seven to one per week.
Endocrine News published a clinical update in Research Highlights on 27 Mar 2026.
The item focuses on Pharma Fridays – March 27, 2026.
Review the original article for the full source wording and details.